Skip to main content

Table 3 Individual development of hemodynamics in patients presenting with manifest PAH at the end of the observation period

From: Effect of ambrisentan in patients with systemic sclerosis and mild pulmonary arterial hypertension: long-term follow-up data from EDITA study